Welcome to our dedicated page for enGene Therapeutics SEC filings (Ticker: engnw), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on enGene Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into enGene Therapeutics's regulatory disclosures and financial reporting.
enGene Holdings Inc. filed a Form S-8 to register securities for employee benefit plans and to reflect non-qualified stock options issued as inducements for hires. The filing notes Inducement Awards granted on April 2, 2025, June 16, 2025, and July 31, 2025, approved under the employment inducement exception to Nasdaq Listing Rule 5635(c)(4).
The document incorporates by reference the company’s Annual Report for the year ended October 31, 2024 (and Amendment No. 1), multiple quarterly reports for 2025, several Form 8-Ks, and exhibits including the amended 2023 Incentive Equity Plan and the 2025 Employee Stock Purchase Plan. Signatures are dated September 11, 2025.
enGene Holdings Inc. reports continued development spending and financing activity while evaluating its ability to continue as a going concern. The company has 100,000,000 authorized common shares with 51,105,807 and 50,976,676 shares issued and outstanding as of July 31, 2025 and October 31, 2024, respectively. The company drew a $22.5 million Tranche 1 term loan advance and has up to $50.0 million available in multiple tranches, subject to milestones and lender approval, with various prepayment fees and an end-of-term charge equal to 5.50% of principal. Operating expenses increased materially due to clinical and manufacturing activity: a $26.2 million increase in detalimogene direct expense and a $7.9 million increase in personnel-related costs year-to-date, with additional increases in G&A and professional fees related to commercialization preparations. The company identified material weaknesses in internal controls around IT change management, user access segregation, and account reconciliations and has implemented remediation steps including new policies, risk assessments, enhanced software controls, and engagement of an accounting firm. The filing emphasizes heavy dependence on the success of detalimogene and lists multiple clinical, regulatory, manufacturing, and financing risks that could affect future operations.
enGene Holdings Inc., a British Columbia company listed on The Nasdaq Stock Market LLC, furnished an update on its recent performance. The company announced its financial results for the third fiscal quarter ended July 31, 2025, and provided these details in a press release.
The press release, dated September 11, 2025, is attached as Exhibit 99.1. The company states that this information is being furnished rather than filed under the Securities Exchange Act of 1934, meaning it is not subject to certain liability provisions or automatically incorporated into other SEC filings. The report is signed by Chief Executive Officer and President Ronald H. W. Cooper.
enGene Holdings Inc. reported a clinical milestone and updated its investor materials. The company reached its target enrollment of 100 patients in Cohort 1, the pivotal cohort of the Phase 2 portion of the LEGEND trial evaluating detalimogene voraplasmid in high-risk, non-muscle invasive bladder cancer that is unresponsive to Bacillus Calmette-Guérin. Cohort 1 focuses on patients with carcinoma in-situ, with or without concomitant papillary disease. enGene also refreshed its Corporate Presentation and furnished it as an exhibit, while a press release describing the enrollment milestone was filed as a separate exhibit.